Phenylketonuria

Enzymatic Defect

• Mutations in the PAH gene (chromosome 12q23.2) result in loss of function of phenylalanine hydroxylase, the hepatic enzyme responsible for converting phenylalanine to tyrosine
• Over 1,000 different mutations have been identified, ranging from complete enzyme loss to partial activity, explaining variable disease severity (classic PKU vs. mild hyperphenylalaninemia)
• Defective PAH protein misfolds, undergoes proteasomal degradation, or retains residual catalytic activity depending on mutation type

Neurotoxicity Mechanisms

• Hyperphenylalaninemia directly inhibits the large neutral amino acid transporter 1 (LAT1), reducing uptake of competing amino acids (tyrosine, tryptophan, leucine) across the blood-brain barrier, leading to secondary deficiencies of neurotransmitter precursors
• Elevated phenylalanine competitively inhibits tyrosine hydroxylase, reducing dopamine, norepinephrine, and epinephrine synthesis, with particularly severe consequences in the prefrontal cortex and striatum
• Phenylalanine metabolites (phenylacetate, phenylpyruvate, phenyllactate) accumulate and produce direct neurotoxic effects through generation of reactive oxygen species and mitochondrial dysfunction
• Deficient tyrosine production impairs synthesis of myelin proteins and reduces availability for melanin synthesis, contributing to myelination defects and hypopigmentation

Secondary Metabolic Effects

• Impaired myelination due to reduced tyrosine availability for protein synthesis, affecting oligodendrocyte function and white matter development during critical developmental windows
• Disruption of neurotransmitter synthesis (dopamine, serotonin via tryptophan) affecting neural plasticity, synaptogenesis, and cognition
• Altered phospholipid metabolism and reduced phosphatidylcholine synthesis necessary for myelin maintenance

Genetic Causes

• Classic PKU: Homozygous or compound heterozygous PAH mutations resulting in <1% residual enzyme activity; accounts for ~75% of PKU cases
• Mild PKU: Mutations conferring 1–3% residual PAH activity; plasma phenylalanine typically 600–1,200 μmol/L
• Mild Hyperphenylalaninemia: Mutations with 3–10% residual activity; plasma phenylalanine 240–600 μmol/L
• Variant PKU (Atypical PKU): Primary defects in cofactor metabolism (tetrahydrofolate reductase, dihydrofolate reductase, dihydropteridine reductase); require BH4 supplementation rather than dietary restriction alone

Risk Factors

• Autosomal recessive inheritance: 25% recurrence risk in siblings; carrier frequency ~1–2% in general population
• Ethnic variation: Higher prevalence in Northern European and Caucasian populations; lower in African and Asian populations
• Consanguinity increases risk in populations with high carrier frequency

Untreated Infants (First Weeks to Months)

• Musty or "mousy" odor of urine and perspiration due to phenylacetic acid accumulation (classic sign, often first noticed by caregivers)
• Irritability, lethargy, poor feeding, vomiting
• Infantile eczema and seborrheic dermatitis
• Fair skin, blonde hair, and blue eyes (hypopigmentation due to competitive inhibition of melanin synthesis)
• Microcephaly and developmental delay becoming apparent by 3–6 months if untreated

Untreated Toddlers and Children

• Severe intellectual disability (IQ <50 if untreated), progressive cognitive decline
• Seizures (20–40% of untreated patients), typically generalized tonic-clonic, often intractable
• Spasticity and hypertonia, particularly in lower extremities; hyperreflexia
• Behavioral abnormalities: hyperactivity, aggression, self-injury, autism spectrum behaviors
• Ataxia, tremor, choreiform movements

Adolescents and Adults (if untreated)

• Severe intellectual disability with behavioral disturbances
• Progressive neurological deterioration: dementia, Parkinson-like features
• Psychiatric manifestations: schizophrenia-like psychosis, mood disorders
• Physical deterioration with loss of ambulation

Early-Treated Patients (Diagnosed by Screening)

• Often asymptomatic or minimally symptomatic with early, consistent dietary management
• Mild learning disabilities or attention-deficit/hyperactivity disorder possible despite treatment adherence
• Growth and development typically normal with dietary adherence

Physical Examination Findings

• Hypopigmented skin and light-colored hair (fair complexion even in darker-skinned populations)
• Microcephaly (if untreated in infancy)
• Spasticity, hyperreflexia, clonus (if untreated)
• Signs of poor compliance (if dietary management inadequate): progressive neurological decline

Newborn Screening (Primary Detection Method)

• Tandem mass spectrometry (MS/MS): Detects elevated phenylalanine on dried blood spot; most sensitive and widely used method
• Phenylalanine >20 mg/dL (>1,200 μmol/L) on initial screening warrants immediate confirmatory testing
• Second-tier testing performed on same sample to distinguish PKU from benign hyperphenylalaninemia
• Elevated phenylalanine-to-tyrosine ratio: Helps differentiate PKU (ratio >3) from secondary causes
• Elevated phenylalanine on repeat sampling (typically 24–48 hours post-initial screen) confirms diagnosis

Confirmatory Testing

• Plasma amino acid quantification by high-performance liquid chromatography (HPLC) or amino acid analyzer: Phenylalanine >1,200 μmol/L confirms PKU; normal <120 μmol/L
• Urine organic acids: Elevated phenylpyruvate, phenyllactate, and phenylacetate confirm hyperphenylalanemia (may be absent in early infancy)
• PAH enzyme activity measurement: Demonstrates enzyme deficiency (performed on liver biopsy or cultured hepatocytes; rarely necessary clinically)

Genetic Testing

• **DNA sequencing of PAH gene**: Identifies specific mutations; useful for:
• Confirming diagnosis when biochemical results ambiguous
• Genetic counseling and family planning
• Prognostication regarding enzyme residual activity and phenotype prediction

Variant PKU Diagnostic Differentiation

• BH4 loading test: Oral tetrahydrofolate (BH4) challenge (20 mg/kg) followed by phenylalanine measurement at 4–6 hours
• Significant phenylalanine reduction (>30% decrease) indicates BH4-responsive PKU (variant PKU)
• No response indicates classic PKU or PAH deficiency
• Pteridine and biopterin levels: Elevated or abnormal pattern in variant PKU; normal in classic PKU

Imaging (If Neurological Manifestations Present)

• Brain MRI: Reveals white matter abnormalities (especially in untreated cases or those with poor dietary compliance):
• Hypomyelination or delayed myelination (T1 hypointensity, T2 hyperintensity)
• Basal ganglia signal abnormalities
• Periventricular white matter involvement
• EEG: May show generalized slowing, sharp waves, or seizure activity in untreated patients

Diagnostic Criteria

• Classic PKU: Plasma phenylalanine >1,200 μmol/L (>20 mg/dL) on two separate measurements; documented PAH enzyme deficiency or biallelic PAH mutations
• Mild PKU: Plasma phenylalanine 600–1,200 μmol/L (10–20 mg/dL)
• Mild Hyperphenylalaninemia: Plasma phenylalanine 240–600 μmol/L (4–10 mg/dL)

First-Line Therapy: Dietary Phenylalanine Restriction (Cornerstone of Management)

• Mechanism: Reduces exogenous phenylalanine intake, lowering plasma levels to safe range (typically target 2–6 mg/dL or 120–360 μmol/L in children <12 years; slightly higher in adolescents/adults: 2–10 mg/dL)
• Medical food (protein substitute): Essential component; replaces natural protein while providing adequate amino acids without phenylalanine
• Examples: Phenyl-Free, Lofenalac, PKU AIFP, Phlexy-Vits
• Should provide 70–80% of total protein intake
• Must contain all essential amino acids, vitamins, minerals to prevent secondary deficiencies
• Natural protein allowance: Carefully calculated based on plasma phenylalanine levels, typically 300–500 mg/day in children; adjusted based on growth, plasma levels, and individual metabolism
• Monitoring: Plasma phenylalanine levels measured monthly in infants <1 year, quarterly in children 1–12 years, and quarterly to semi-annually in adolescents/adults
• Adjust phenylalanine intake when levels drift outside target range
• Tighter control (2–6 mg/dL) in young children to optimize neurological development

Adjunctive Pharmacotherapy

• BH4 (sapropterin dihydrochloride) supplementation: For BH4-responsive PKU (variant PKU)
• Dosage: Initial 10 mg/kg/day divided in 2–3 doses; increase to 20 mg/kg/day if responsive
• Mechanism: Increases PAH enzyme activity by stabilizing PAH protein and improving cofactor availability
• Effectiveness: ~20–30% of PKU patients show responsiveness; may allow modest relaxation of dietary restriction
• Monitoring: Perform BH4 loading test (see Diagnosis) to identify candidates; measure plasma phenylalanine response at 4–6 hours post-dose
• Tyrosine supplementation: May be beneficial in some patients with nutritional deficiency, though usually provided in adequate amounts in medical food; typically 100–200 mg/kg/day if supplemented
• Micronutrient supplementation: Ensure adequate vitamins (especially B vitamins, folate), iron, zinc, calcium in context of restricted diet

Maternal Phenylketonuria (Maternal PKU) Management

• Strict dietary control before conception and during pregnancy essential to prevent maternal hyperphenylalaninemia-induced fetal damage
• Target plasma phenylalanine <360 μmol/L (6 mg/dL) throughout pregnancy
• Intensive monitoring: Plasma phenylalanine measured weekly in first trimester, biweekly thereafter
• Continuation of medical food and dietary restriction throughout pregnancy and lactation
• Folic acid supplementation (4–5 mg daily) important to prevent neural tube defects

Non-Pharmacological Measures

• Nutritional counseling by metabolic nutritionist specialized in PKU management; essential for dietary compliance
• Periodic review of protein intake and natural food choices; patient/family education critical
• Exercise and activity planning: Standard recommendations; dietary adjustments may be needed around periods of increased metabolic demand
• Psychosocial support: Counseling for families managing long-term dietary restrictions; support groups valuable

Monitoring and Follow-up

• Plasma phenylalanine levels (frequency as above) remain cornerstone of monitoring; target adjusted by age
• Growth monitoring: Height, weight, head circumference in children; anthropometric measures in adults
• Neurodevelopmental assessment: Formal psychological testing at baseline and periodically (especially important if non-compliance suspected)
• Compliance assessment: Regular dietary review, discussion of challenges, reinforcement of dietary adherence importance
• Metabolic panel including liver function, lipids, iron studies; assess for nutritional deficiencies
• Transition planning: Careful management during transition from pediatric to adult care; increased risk of non-compliance in adolescence

Neurological Complications (Untreated or Poorly Managed)

• Severe intellectual disability and cognitive decline: Most serious complication; largely preventable with early diagnosis and treatment; degree proportional to duration and severity of hyperphenylalaninemia
• Seizure disorders: Occurs in 20–40% of untreated patients; can be intractable; may develop even with late treatment initiation
• Spasticity and hypertonia: Progressive neurological deterioration; pyramidal signs predominate
• White matter disease: Progressive demyelination, particularly in untreated cases; may partially reverse with adequate dietary control if initiated before irreversible damage
• Movement disorders: Parkinsonism, dystonia, tremor in untreated adolescents/adults

Psychiatric and Behavioral Complications

• Autism spectrum disorder: Increased prevalence in PKU; may be partly preventable with early treatment
• Schizophrenia-like psychosis: Can develop in untreated or inadequately treated adolescents/adults
• ADHD and behavioral disturbances: Common; may persist despite adequate dietary control, suggesting epigenetic/developmental mechanisms
• Mood disorders: Depression, anxiety in adolescents/adults with PKU

Metabolic Complications

• Secondary nutritional deficiencies: Iron-deficiency anemia, zinc deficiency, B vitamin deficiency if medical food composition inadequate
• Bone health: Impaired bone mineral density despite adequate dietary management; likely multifactorial (malabsorption, reduced weight-bearing, chronic metabolic acidosis from medical food)
• Growth failure: Uncommon with adequate management, but may occur with severe dietary restriction or poor compliance

Dermatological and Pigmentation Complications

• Eczema and seborrheic dermatitis: Common in early infancy; usually improves with age
• Hypopigmentation: Cosmetically apparent; represents permanent consequence of reduced tyrosine availability during critical developmental period

Ocular Complications

• Ectopia lentis: Rare but may occur (more common in homocystinuria)
• Refractive errors and visual problems: Increased prevalence; warrants routine ophthalmologic evaluation

Maternal PKU Complications (Untreated Maternal Hyperphenylalaninemia)

• Congenital heart defects: Particularly ventricular septal defects, tetralogy of Fallot
• Intellectual disability in offspring: Even if offspring is heterozygous (carrier); caused by in utero exposure to maternal hyperphenylalaninemia
• Intrauterine growth restriction and low birth weight
• Microcephaly in offspring
• Behavioral and learning disabilities in offspring
• Cleft palate and other craniofacial abnormalities (rare)

Management of Complications

• Seizure management: Standard antiepileptic drugs (levetiracetam, valproic acid, lamotrigine) if seizures develop; address underlying metabolic control
• Behavioral/psychiatric management: Psychopharmacotherapy as indicated; interdisciplinary approach with neurology, psychiatry, psychology
• Rehabilitation: Physical therapy, occupational therapy if neurological deficits develop
• Bone health optimization: Calcium and vitamin D supplementation; weight-bearing exercise; periodic DEXA scanning in adolescents/adults

Early-Treated Patients (Diagnosed by Newborn Screening, Treatment Initiated <2 weeks of life)

• Excellent neurodevelopmental outcome if dietary control maintained consistently
• Normal to near-normal IQ (average IQ 85–95) in most patients with lifetime dietary adherence

• Autosomal recessive, enzyme is phenylalanine hydroxylase: the block converts phenylalanine into a toxic dead end and makes tyrosine a conditionally essential amino acid — this single sentence explains the intellectual disability, the musty/mousy body odor (phenylacetate), and the hypopigmentation (less substrate for melanin) all at once.
• The classic triad in a stem: fair-haired, blue-eyed, hypopigmented infant + musty odor + developmental regression with microcephaly and seizures beginning after the first few months of life. Symptoms are absent at birth because the placenta clears fetal phenylalanine.
• Best next step in a positive newborn screen: quantitative plasma amino acids (phenylalanine and phenylalanine:tyrosine ratio), not repeat dried blood spot alone. Screening is universal in the US via the HRSA-endorsed Recommended Uniform Screening Panel, and the USPSTF recommends newborn PKU screening. A specimen drawn too early — before adequate protein feeding — is the classic cause of a false-negative screen.
• The association examiners love: maternal PKU: a mother off diet exposes a genetically normal (often heterozygous) fetus to phenylalanine, producing microcephaly, intellectual disability, congenital heart disease, and IUGR. Per ACMG guidance, control must be achieved before conception, not after the positive pregnancy test.
• The common distractor: "just restrict phenylalanine." In cofactor (BH4 synthesis or dihydropteridine reductase) defects — malignant hyperphenylalaninemia — BH4 is also required by tyrosine and tryptophan hydroxylases, so diet alone leaves the child neurologically devastated. These patients need BH4 plus neurotransmitter precursors (levodopa/carbidopa and 5-hydroxytryptophan). Always check pterins and DHPR activity.
• Adjuncts worth naming: sapropterin (synthetic BH4) for BH4-responsive genotypes, and pegvaliase, a PEGylated phenylalanine ammonia lyase for adults, which carries an anaphylaxis boxed warning and REMS requirement.
• Aspartame is a phenylalanine source — the mandated food label warning is a favorite one-liner.
• Do not confuse: alkaptonuria (homogentisate oxidase, urine darkens on standing, ochronosis) and tyrosinemia sit downstream in the same pathway.
• Treatment is lifelong, not stopped in adolescence; relaxation causes executive dysfunction and white matter changes.